Facebook Linkedin Mail Twitter Youtube
  • Home
  • Latest News
  • Features
  • Vascular News
  • Profiles
  • Media
    • Videos
    • Podcasts
  • Events
  • Supplements
  • Past Issues
  • Subscribe
Search
Facebook Linkedin Mail Twitter Youtube
Venous News Venous News
Venous News Venous News
  • Home
  • Latest News
  • Features
  • Vascular News
  • Profiles
  • Media
    • Videos
    • Podcasts
  • Events
  • Supplements
  • Past Issues
  • Subscribe

    Charing Cross (CX) Symposium 2025

    31st July 2024
    267

    W: https://www.cxsymposium.com/


    Jocelyn Hudson

    website-logo@4x

    website-logo@4x
    VTE

    Braided as compared with laser-cut nitinol stents achieve favourable primary patency...

    4th September 2020
    Mercator Bullfrog

    Mercator announces enrolment of first patient in DEXTERITY-AFP clinical trial treating...

    4th November 2021
    Artificial intelligence DVT

    Artificial intelligence tool predicts DVT risk following endovenous thermal ablation

    19th June 2025
    venous valve

    Answering the questions of appropriate outcomes measures after intervention for deep...

    29th May 2025
    Stephen Black viva 2019

    No longer a ‘one-trick shop’: Venous becomes core pillar of CX...

    1st April 2025

    Thrombectomy gold rush set to follow ATTRACT study, experts argue

    22nd July 2024
    Kathleen Oszvath

    Kathleen Ozsvath

    13th March 2025

    Kush Desai

    24th October 2024

    Gloria Salazar

    10th June 2024
    Venous News

    Write to us
    Editors: Jocelyn Hudson [email protected] and Éva Maplass [email protected]
    Advertising:
    Rav Pankhania [email protected]
    Nicole Schmit     [email protected]


    United Kingdom:

    BIBA Medical, Europe
    526 Fulham Road, Fulham, London, SW6 5NR
    TEL: +44 (0)20 7736 8788
    Email: [email protected]

    United States:

    BIBA Medical, North America
    155 North Wacker Drive, Suite 4250, Chicago, IL 60606
    TEL: +1 949 723 9309
    Email: [email protected]

    Terms and Conditions | Privacy Policy

    Facebook Linkedin Mail Twitter Youtube